HOME >> MEDICINE >> NEWS
Iressa news backgrounder

It is a drug suffused in promise, a next-generation therapy that has shown glimmers of powerful potential. Iressa is the kind of treatment that oncologists dream of - a pill that can be swallowed once a day, a non-toxic therapy that causes few side effects. For 10 percent of patients who have tried it, people who have no other options left for them, Iressa seems to make the difference between life and death. Another 30 percent to 40 percent of patients who have used the drug have a better, if not a longer, life.

But for most patients, Iressa does not shrink their cancer. That fact has become a challenge to researchers at The University of Texas M. D. Anderson Cancer Center. They are dedicated to solving the central puzzle that Iressa, and similar other targeted therapies, pose - what are the cancers that may best respond, and which patients will benefit?

M. D. Anderson researchers have been at the forefront of testing Iressa, as well as a slew of other experimental drugs that target critical cancer cell pathways. They have been involved in all phases of clinical trials looking at the effectiveness of Iressa in common lung cancer, work that helped lead to federal Food and Drug Administration approval of the drug in early 2003 for use when standard therapy has not helped lung cancer patients.

Now, investigators at M. D. Anderson are testing Iressa in malignant brain cancer and are poised to study it in a number of cancers, including head and neck, breast, and prostate, along with further investigations in lung cancer.

"M. D. Anderson is one of the leading institutions in developing targeted therapies such as Iressa," says Frank Fossella, M.D., professor in the Department of Thoracic/Head and Neck Medical Oncology, who has treated many lung and other head and neck cancers where it has shown tantalizing benefit.

"So far, Iressa has been a good news, bad news story. The response rates are not as high as we would have liked
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center
16-Oct-2003


Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Gene mutations predict which lung cancers will respond to Iressa
2. Iressa news backgrounder: Testing of smart drug expands at M. D. Anderson Cancer Center
3. Chemoprevention backgrounder: Working for a future of cancer chemoprevention
4. Cancer gene therapy news backgrounder: New ideas fuel next generation gene therapy research
5. Cancer markers news backgrounder: Future of cancer diagnosis, treatment lies in tumor barcode

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Iressa news backgrounder

(Date:8/27/2014)... Delta, a reliable supplier of high quality ... D7R Dozers to its used bulldozer collection. ... that all these items are offered with deep discounts. ... Delta’s market share in the coming September. , ... offer; he has much confidence in the discounted Used ...
(Date:8/27/2014)... Philadelphia, PA. Inc. magazine ranked Holganix as No. ... exclusive ranking of the nation’s fastest-growing privately held companies. ... most important segment of the economy - America’s independent ... members of the Inc. 500 list include Dell, LinkedIn, ... world’s greatest companies have had their start on the ...
(Date:8/27/2014)... Diego, CA (PRWEB) August 27, 2014 ... insurance policies will now be easier for the public ... insurance prices that are promoted in all 50 states ... . , The different insurers that are generating ... made it possible for adults to use the programmed ...
(Date:8/27/2014)... August 27, 2014 Today, Zane Benefits, ... on compliance tips for administering a premium reimbursement plan. ... in full effect, compliance is top of mind for ... to individual health insurance and premium reimbursement, there are ... In the 35 minute webinar, Zane Benefits President, Rick ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 Top 10 Best ... compared many Linux hosting suppliers and announced iPage, Bluehost and ... USA, UK, Canada, Australia and Europe to buy useful hosting ... the most reliable suppliers, iPage has been serving ... years’ development, it has grown into a leader in the ...
Breaking Medicine News(10 mins):Health News:Reliable Supplier Delta Adds New Items To Its Used Bulldozer Collection 2Health News:Inc Magazine Unveils 33rd Annual List of America's Fastest-Growing Private Companies - the Inc. 500 2Health News:Home Insurance Prices for All 50 States Now Supplied at Consumer Insurance Portal Online 2Health News:Zane Benefits Announces Upcoming Webinar on Compliance 2Health News:Well-known SEO Hosts Review Site Top10BestSEOHosting.com Recommends iPage, Bluehost and GoDaddy To Webmasters 2
(Date:8/27/2014)... 27, 2014 Reportbuyer.com has added ... Co-development Terms & Agreements in Pharma, Biotech ... The Co-development Terms and Agreements ... comprehensive understanding and unprecedented access to the ... the worlds leading life science companies. ...
(Date:8/27/2014)... and MENLO PARK, Calif. , Aug. ... DMPI), developer of advanced cancer therapeutics , will ... Annual Rodman & Renshaw Global Investment Conference, sponsored by ... take place Tuesday, September 9th at 2:55 p.m. EDT ... New York Palace Hotel in New York ...
(Date:8/27/2014)... , Aug. 27, 2014 Research ... "Global Pulse Oximeter Industry Report 2014" report to ... Industry Report 2014 is a professional and in-depth study ... industry. The report provides a basic overview ... chain structure. The pulse oximeter market analysis is provided ...
Breaking Medicine Technology:Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 2Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 3Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 4Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 5Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 6Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 7DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4Global Pulse Oximeter Industry Report 2014 2
Cached News: